{"id":"NCT01753336","sponsor":"Ipsen","briefTitle":"Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia","officialTitle":"A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport® Using 2 mL Dilution In Adults With Cervical Dystonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2012-12-20","resultsPosted":"2017-05-04","lastUpdate":"2019-08-07"},"enrollment":112,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Dystonia"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]}],"arms":[{"label":"Dysport®","type":"EXPERIMENTAL"}],"summary":"The purpose of the protocol is to assess the long term safety of repeat treatment cycles of Dysport® 500 U using 2 mL dilution scheme for the treatment of Cervical Dystonia. This is an extension study to study A-TL-52120-169 (hereafter referred to as Study 169).","primaryOutcome":{"measure":"TWSTRS Total Score at Week 4 and Week 12 for Treatment Cycles 1, 2 and 3.","timeFrame":"Week 4 and 12 of treatment cycles 1, 2 and 3 (12 - 16 weeks duration each)","effectByArm":[{"arm":"Total Dysport®","deltaMin":37.7,"sd":13.58}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":17},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["32884828"],"seeAlso":["https://clinicaltrials.gov/ct2/show/NCT01753310?term=A-TL-52120-169&rank=1"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":112},"commonTop":["Muscular Weakness","Neck Pain","Dysphagia","Headache","Fall"]}}